Full name

A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, When Given as a Second Dose to Healthy Children, 3 Months After the Administration of a First Dose at 12 to 15 Months of Age

NCT Number
NCT06806137
Geography
Non-US
Locations

Dominican Republic

Primary Endpoints
  • Percentage of participants with seroresponse to Varicella Zoster Virus (VZV) anti- glycoprotein E (gE) IgG for 2 doses of VNS vaccine compared to 2 doses of VV. At Day 133 (43 days post-dose 2).
  • Geometric Mean Concentration (GMC) of anti-VZV gE IgG for 2 doses of VNS vaccine compared to 2 doses of VV. At Day 133 (within 43 days post-dose 2)
Order
0
Disease
Varicella
Menu title
Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
Version
AAFP/FMX 2025
Phase
3a
Status
Recruiting